Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05777850
Other study ID # FASD-HP trial
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 25, 2022
Est. completion date April 2025

Study information

Verified date March 2023
Source Hospital General Universitario de Alicante
Contact Laura Valverde Soria
Phone 687198597
Email lauravalverdesoria@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of cavotricuspid isthmus (CTI) dependent flutter ablation is the bidirectional conduction block of CTI. The probability of achieving a permanent bidirectional block at the CTI depends, mainly, on the ablation energy applied and the quality of the obtained lesion. Among the factors that determine the lesion's quality those which have the bigger impact are catheter stability, contact force, power and duration of energy application and the temperature reached at depth.This is a multicenter 1:1 randomized, blinded (open for the operator) study. Two CTI ablation strategies are compared: 1) conventional treatment branch which consists of individual 25-40 W applications of unlimited duration until achieving in each application the minimum value of one of the currently accepted and used lesion markers (Ablation Index >500 at the anterior half of the CTI and >400 at the posterior half with de CARTO 3 system; 2) experimental treatment branch consistent of CTI block using individual high power (90W) short duration (4 seconds) point-by-point applications. The main objective of this study is assessing the non-inferiority of the efficacy and safety of high-power short-duration ablation in patients undergoing typical atrial flutter ablation. Secondary objectives include the comparison of total radiofrequency time, number of applications, number of steam pops, percentage of reconnections, procedure duration, pain during the procedure and time to atrial flutter recurrence.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date April 2025
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with cavotricuspid isthmus dependent flutter referred to ablation - Patients clinically and hemodynamically stable. - Patients who give informed consent. Exclusion Criteria: - Refusal to participate in the register or inability to understand the informed consent. - Age under 18. - Patients who have already undergone previous flutter ablation procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Conventional cavotricuspid isthmus ablation
Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
High-power short-duration ablation
Point-by-point 90W applications at the CTI ablation during 4 seconds.

Locations

Country Name City State
Spain Hospital General Doctor Balmis Alicante Alicante A

Sponsors (1)

Lead Sponsor Collaborator
Jose Luis Ibañez Criado

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety primary outcome: incidence of procedure-related complications. Number of procedure-related complications from the time of the ablation until the last follow-up visit. One year
Primary Efficacy primary outcome: typical atrial flutter recurrence. Incidence of typical atrial flutter recurrence during a one-year follow-up period. To be considered clinically relevant the recurrence must be documented by a full EKG made because of patients' symptoms or any typical atrial flutter detected by an EKG, 24h Holter-EKG or events-monitoring device that will be performed at least at a 6 months and 12 months follow-up visits. One year
See also
  Status Clinical Trial Phase
Completed NCT03593486 - Low-Level EMF Stimulation for Paroxysmal Atrial Fibrillation N/A
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Active, not recruiting NCT06124690 - Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas N/A
Recruiting NCT05251545 - Randomized Trial: High Power Short Duration Versus Ablation Index N/A
Not yet recruiting NCT04780438 - Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation. Early Phase 1
Active, not recruiting NCT03695484 - Registry Evaluating AF Ablation Techniques
Not yet recruiting NCT05565183 - Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation. N/A
Recruiting NCT06160076 - Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2
Not yet recruiting NCT05575544 - Electroacupuncture Intervention in Catheter Ablation of Atrial Fibrillation N/A
Recruiting NCT04678258 - Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation N/A
Active, not recruiting NCT01630031 - Contact Force Sensing and Pulmonary Vein Isolation N/A
Completed NCT04896424 - Vagal Response and Cardiac Autonomic Modulation. Insides From Cryoballoon Ablation N/A
Completed NCT04906720 - Post-Ablation Pericarditis Reduction Study Phase 2
Not yet recruiting NCT05273645 - PrOgnosis Following Esophageal fisTula formaTion in Pts Undergoing cathetER Ablation for AF Study
Completed NCT03140631 - Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Phase 4
Active, not recruiting NCT03514693 - Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation N/A
Recruiting NCT03832959 - Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study. N/A
Not yet recruiting NCT05716581 - Prognostic Factors for Ablation of Atrial Fibrillation
Active, not recruiting NCT04405258 - Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial Phase 4
Completed NCT03340922 - MANual vs. automatIC Local Activation Time Annotation for Guiding Premature Ventricular Complex Ablation Phase 4